Kisunla Brain Injury Lawsuit

Brain Bleeding or Swelling After Taking Kisunla?

Fill out the form and see if you qualify today!

Compensation may be available image description
image description

Kisunla Brain Injury Attorneys

Seeger Weiss is currently investigating these matters. If you think you have a case, get in touch today for a free consultation.

Kisunla Brain Injury Lawsuit

Did you or a loved one experience brain bleeding or swelling after taking the Alzheimer's drug Kisunla (donanemab)?
Compensation may be available

Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has been linked to dangerous brain bleeding, swelling, and other serious complications in patients. On March 27, 2025, the European Medicines Agency (EMA) refused marketing authorization for Kisunla, concluding that the drug’s modest benefits do not outweigh the significant risks of potentially fatal brain injuries.

Recent investigations have revealed concerning safety issues with Kisunla, particularly related to a side effect known as amyloid-related imaging abnormalities (ARIA), which involves swelling and potential bleeding in the brain. The evidence suggests that patients were not adequately warned about these serious risks before taking the medication.

If you or a loved one took Kisunla for Alzheimer’s disease and experienced brain bleeding, swelling, or other serious complications, you may be eligible for compensation.

Serious Brain Complications from Kisunla

Kisunla (donanemab) is a monoclonal antibody designed to attach to and reduce amyloid beta plaques in the brain of Alzheimer’s patients. While approved in the US, Japan, China and UK, the medication has been rejected by European regulators specifically due to safety concerns.

Patients taking Kisunla have reported experiencing:

  • Brain bleeding (cerebral hemorrhage)
  • Brain swelling (cerebral edema)
  • Amyloid-related imaging abnormalities (ARIA)
  • Severe headaches
  • Confusion and disorientation
  • Seizures
  • Hospitalization
  • Permanent neurological damage
  • Death

According to data reviewed by European regulators, ARIA occurred in 36.8% of people who received Kisunla compared to 14.9% receiving placebo. Serious ARIA events occurred in 1.6% of Kisunla patients, resulting in multiple deaths during clinical studies.

Do not stop taking a prescribed medication or stop using a prescribed medical device without first consulting with your doctor. Discontinuing a prescribed medication or use of a prescribed medical device without your doctor’s advice can result in injury or death. Notwithstanding claims relating to certain drugs and medical devices, the drug or medical device may remain approved by the U.S. FDA.

High-Risk Groups Not Properly Warned

Research has shown that certain patients are at significantly higher risk for brain bleeding when taking Kisunla. People with the ApoE4 gene variant face substantially higher risks of developing serious complications, yet many were not adequately informed of this risk.

A major investigation by The New York Times revealed that during clinical trials:

  • Patients with genetic profiles that made them vulnerable to brain injuries were not informed of their personal risk
  • Many experienced what researchers classified as “severe” brain bleeding
  • Information about individual risk factors was systematically withheld
  • Patients were unable to make informed decisions about their treatment

Even after Kisunla’s approval, concerns remain about whether patients and healthcare providers are being fully informed about these risks.

Regulatory Action and Safety Concerns

The European Medicines Agency formally recommended against approving Kisunla in March 2025, stating that the benefits of the medication “were not large enough to outweigh the risks of potentially fatal events due to ARIA.”

The EMA noted:

  • Three deaths occurred in Kisunla clinical trials due to ARIA complications
  • Even in restricted populations with lower genetic risk, serious ARIA events still occurred
  • The drug’s cognitive benefits were modest (slowing decline by only a few months)
  • The risk-benefit profile was unacceptable even with enhanced monitoring

If you or a loved one took Kisunla for Alzheimer’s disease and experienced brain bleeding, brain swelling, or other serious complications, you may be eligible for compensation. Contact us today for a free consultation regarding your legal rights.

Sources:

Compensation may be available
Awards

Recognized for excellence

No aspect of this or any advertisement has been approved by the Supreme Court of New Jersey.

best law firms 2025

In the 2025 edition of Best Law Firms, ranked by Best Lawyers, Seeger Weiss was recognized nationally for the firm’s representation of plaintiffs in mass tort and class action litigation. Best Law Firms is issued by Best Lawyers.

Learn more about their selection methodology
seeger weiss chambers 2024

For the fourth consecutive year, Chambers honored Seeger Weiss with the highest firm ranking, Band 1, in the 2024 Chambers USA Product Liability: Plaintiffs guide. Partners Chris Seeger, Dave Buchanan & Ben Barnett were also featured in the guide.

Learn more about their selection methodology
law.com elite trail lawyers 2023

Seeger Weiss was recognized as Mass Torts Firm of the Year at The National Law Journal’s 2023 Elite Trial Lawyers award ceremony. The 2023 Mass Torts Firm of the Year award is issued by The National Law Journal.

Learn more about their selection methodology
l image

Law360 selected Seeger Weiss’s product liability practice as a 2023 Practice Group of the Year. The award honors “attorney teams behind litigation wins and major deals that resonated throughout the legal industry this past year.”

Learn more about their selection methodology
Testimonials

What people have to say about us

The settlement has significantly impacted my life and future financial security. It will allow me to maintain and enjoy my quality of life in my new home near my daughter for an extended time.

Linda J.

I am so very thankful to the Seeger Weiss law firm for their dedication and support …

Bernard S.

Seeger Weiss made sure I was taken care of.

Keith M.

They treated me not as a client, but as family.

Debbie D.
Results may vary depending on your particular facts and legal circumstances.
Faq

Frequently Asked Questions

  • About Seeger Weiss

    Seeger Weiss is best known for multidistrict mass torts and class actions in both state and federal court. From offices in New York, New Jersey, and Pennsylvania, and Massachusetts, the firm has represented over 10,000 individuals, companies, and governments across the U.S. who have been injured or defrauded on a massive scale.

    Since its founding in 1999, it has led many of the most complex and high-profile cases in the country: the National Prescription Opiate Litigation; 3M Combat Arms Earplug Products Liability Litigation; the ongoing “Dieselgate” scandal; the sprawling multistate litigation on behalf of survivors of child sexual abuse; and the Football League Players’ Concussion Injury Litigation.

    Seeger Weiss doesn’t simply “collect” clients for other lawyers to serve. We go to court and get results, having achieved multiple recoveries in the hundreds of millions and billions of dollars on behalf of large classes of injured clients. Whatever the case, we have the experience and resources necessary to go toe-to-toe with the biggest and best-funded corporations in America.

    Prior results do not guarantee or predict a similar outcome in any future matter.

  • Who am I talking to when I call Seeger Weiss?

    Almost of our calls are initially handled by our talented reception team. Depending on the nature of the call, they may connect you to one of Seeger Weiss’s intake specialists (for prospective clients) or to one of our case management paralegals (for current clients). These teams are here to answer your questions, provide context, and help guide you through process of becoming a client or of pursuing your case in court.

  • Do I have to pay?

    The vast majority of the work Seeger Weiss does is on a contingency basis. That means we are paid only once we have secured financial compensation via trial or settlement—usually a percentage of the total award. Individual retainer agreements, which prospective clients must review and sign to retain Seeger Weiss as their legal representation, will share information on how your contingency fee works.

  • I just signed a retainer, what happens next?

    Once you’ve signed a retainer agreement with Seeger Weiss, the firm becomes your legal representation. For the firm, our next step is to gather as much information about your case as possible. Typically, that means you’ll sign authorization forms that allow us to speak on your behalf to or obtain information from other organizations and institutions, such as a primary care physician’s office or a hospital.

Brain bleeding or swelling after taking the Alzheimer's drug Kisunla (donanemab)?

Free Case Evaluation